[1]
|
Banaudha, K., Kumar, V. and Verma, M. (2018) Challenges and Opportunities in Social Epigenomics and Cancer. Methods in Molecular Biology, 1856, 233-243. https://doi.org/10.1007/978-1-4939-8751-1_13
|
[2]
|
Holstein, E., Dittmann, A., Kääriäinen, A., et al. (2021) The Burden of Post-Translational Modification (PTM)-Disrupting Mutations in the Tumor Matrisome. Cancers (Basel), 13, Article No. 1081. https://doi.org/10.3390/cancers13051081
|
[3]
|
Guo, P., Chen, W., Li, H., et al. (2018) The Histone Acetylation Modifications of Breast Cancer and Their Therapeutic Implications. Pathology and Oncology Research, 24, 807-813. https://doi.org/10.1007/s12253-018-0433-5
|
[4]
|
Attar, N. and Kurdistani, S.K. (2017) Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. Cold Spring Harbor Perspectives in Medicine, 7, a026534. https://doi.org/10.1101/cshperspect.a026534
|
[5]
|
Kraus, W.L., Manning, E.T. and Kadonaga, J.T. (2000) Bio-chemical Analysis of Distinct Activation Functions in p300 That Enhance Transcription Initiation with Chromatin Tem-plates. Molecular and Cellular Biology, 19, 8123-8135.
https://doi.org/10.1128/MCB.19.12.8123
|
[6]
|
Wang, F., Marshall, C.B. and Ikura, M. (2013) Transcription-al/Epigenetic Regulator CBP/p300 in Tumorigenesis: Structural and Functional Versatility in Target Recognition. Cellular and Molecular Life Sciences, 70, 3989-4008.
https://doi.org/10.1007/s00018-012-1254-4
|
[7]
|
Delvecchio, M., Gaucher, J., Aguilar-Gurrieri, C., et al. (2013) Structure of the p300 Catalytic Core and Implications for Chromatin Targeting and HAT Regulation. Nature Structural & Molecular Biology, 20, 1040-1046.
https://doi.org/10.1038/nsmb.2642
|
[8]
|
Zhang, Y., Xue, Y., Shi, J., et al. (2018) The ZZ Domain of p300 Mediates Specificity of the Adjacent HAT Domain for Histone H3. Nature Structural & Molecular Biology, 25, 841-849. https://doi.org/10.1038/s41594-018-0114-9
|
[9]
|
Bhaumik, P., Davis, J., Tropea, J.E., Cherry, S., Johnson, P.F. and Miller, M. (2014) Structural Insights into Interactions of C/EBP Transcriptional Activators with the Taz2 Domain of p300. Acta Crystallographica. Section D, Biological Crystallography, 70, 1914-1921. https://doi.org/10.1107/S1399004714009262
|
[10]
|
Dancy, B.M. and Cole, P.A. (2015) Protein Lysine Acetylation by p300/CBP. Chemical Reviews, 115, 2419-2452.
https://doi.org/10.1021/cr500452k
|
[11]
|
Zhu, G., Pei, L., Li, Y. and Gou, X. (2020) EP300 Mutation Is Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Bladder Cancer Patients. Aging (Albany NY), 12, 2132-2141.
https://doi.org/10.18632/aging.102728
|
[12]
|
Bi, Y., Kong, P., Zhang, L., et al. (2019) EP300 as an Oncogene Cor-relates with Poor Prognosis in Esophageal Squamous Carcinoma. Journal of Cancer, 10, 5413-5426. https://doi.org/10.7150/jca.34261
|
[13]
|
Vannam, R., Sayilgan, J., Ojeda, S., et al. (2021) Targeted Degradation of the Enhancer Lysine Acetyltransferases CBP and p300. Cell Chemical Biology, 28, 503-514. https://doi.org/10.1016/j.chembiol.2020.12.004
|
[14]
|
Suganuma, T., Kawabata, M., Ohshima, T., et al. (2002) Growth Suppression of Human Carcinoma Cells by Reintroduction of the p300 Coactivator. Proceedings of the National Academy of Sciences of the United States of America, 99, 13073-13078. https://doi.org/10.1073/pnas.192586699
|
[15]
|
Seo, G.-Y., Park, S.-R. and Kim, P.-H. (2009) Analyses of TGF-beta1-Inducible Ig Germ-Line Gamma2b Promoter Activity: Involvement of Smads and NF-kappaB. European Journal of Immunology, 39, 1157-1166.
https://doi.org/10.1002/eji.200838732
|
[16]
|
Kim, K.B., Kabra, A., Kim, D.W., et al. (2022) KIX Domain Deter-mines a Selective Tumor-Promoting Role for EP300 and Its Vulnerability in Small Cell Lung cancer. Science Advances, 8, eabl4618.
https://doi.org/10.1126/sciadv.abl4618
|
[17]
|
Garcia-Carpizo, V., Ruiz-Llorente, S., Sarmentero, J., et al. (2019) CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines. Molecular Cancer Research, 17, 720-730.
https://doi.org/10.1158/1541-7786.MCR-18-0719
|
[18]
|
Bryan, E.J., Jokubaitis, V.J., Chamberlain, N.L., et al. (2002) Mutation Analysis of EP300 in Colon, Breast and Ovarian Carcinomas. International Journal of Cancer, 102, 137-141. https://doi.org/10.1002/ijc.10682
|
[19]
|
Qian, M., Zhang, H., Kham, S.K., Liu, S., et al. (2017) Whole-Transcriptome Sequencing Identifies a Distinct Subtype of Acute Lymphoblastic Leukemia with Predominant Genomic Abnormalities of EP300 and CREBBP. Genome Research, 27, 185-195. https://doi.org/10.1101/gr.209163.116
|
[20]
|
Henikoff, S. and Shilatifard, A. (2011) Histone Modification: Cause or Cog? Trend in Genetics, 27, 389-396.
https://doi.org/10.1016/j.tig.2011.06.006
|
[21]
|
Wang, Z., Zang, C., Cui, K., Schones, D.E., et al. (2009) Ge-nome-Wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes. Cell, 138, 1019-1031. https://doi.org/10.1016/j.cell.2009.06.049
|
[22]
|
Henry, R.A., Kuo, Y.M. and Andrews, A.J. (2013) Differences in Specificity and Selectivity between CBP and p300 Acetylation of Histone H3 and H3/H4. Biochemistry, 52, 5746-5759. https://doi.org/10.1021/bi400684q
|
[23]
|
Das, C., Lucia, M.S., Hansen, K.C., et al. (2009) CBP/p300-Mediated Acetylation of Histone H3 on Lysine 56. Nature, 459, 113-117. https://doi.org/10.1038/nature07861
|
[24]
|
de Almeida Nagata, D.E., Chiang, E.Y., Jhunjhunwala, S., et al. (2019) Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. Cell Reports, 27, 269-281.e4.
https://doi.org/10.1016/j.celrep.2019.03.008
|
[25]
|
Huang, Y.H., Cai, K., Xu, P.P., et al. (2021) CREBBP/EP300 Mutations Promoted Tumor Progression in Diffuse Large B-Cell Lymphoma through Altering Tumor-Associated Mac-rophage Polarization via FBXW7-NOTCH-CCL2/ CSF1 Axis. Signal Transduction and Targeted Therapy, 6, Article No. 10. https://doi.org/10.1038/s41392-020-00437-8
|
[26]
|
Liu, Y., Wang, X., Zhu, Y., Cao, Y., et al. (2022) The CTCF/LncRNA-PACERR Complex Recruits E1A Binding Protein p300 to Induce Pro-Tumour Macrophages in Pancre-atic Ductal Adenocarcinoma via Directly Regulating PTGS2 Expression. Clinical and Translational Medicine, 12, e654. https://doi.org/10.1002/ctm2.654
|
[27]
|
Narita, T., Ito, S., Higashijima, Y., et al. (2021) Enhancers Are Activated by p300/CBP Activity-Dependent PIC Assembly, RNAPII Recruitment, and Pause Release. Molecular Cell, 81, 2166-2182.
https://doi.org/10.1016/j.molcel.2021.03.008
|
[28]
|
Kouzarides, T. (2000) Acetylation: A Regulatory Modification to Rival Phosphorylation? EMBO Journal, 19, 1176- 1179. https://doi.org/10.1093/emboj/19.6.1176
|
[29]
|
Choi, J.-R., et al. (2017) p300-Mediated Acetylation Increased the Protein Stability of HIPK2 and Enhanced Its Tumor Suppressor Function. Scientific Reports, 7, Article No. 16136. https://doi.org/10.1038/s41598-017-16489-w
|
[30]
|
Mahmud, Z., Gomes, A.R., Lee, H.J., et al. (2019) EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity via Modulating FOXO3-Acetylation and Activity in Breast Cancer. Cancers (Basel), 11, Article No. 1067.
https://doi.org/10.3390/cancers11081067
|
[31]
|
Chocarro-Calvo, A., García-Martínez, J.M., Ardila-González, S., et al. (2013) Glucose-Induced Â-Catenin Acetylation Enhances Wnt Signaling in Cancer. Molecular Cell, 49, 474-486. https://doi.org/10.1016/j.molcel.2012.11.022
|
[32]
|
Feng, L.J., Lin, T.X., Uranishi, H., et al. (2005) Functional Analysis of the Roles of Posttranslational Modifications at the p53 C Terminus in Regulating p53 Stability and Activity. Molecular and Cellular Biology, 25, 5389-5395.
https://doi.org/10.1128/MCB.25.13.5389-5395.2005
|
[33]
|
Pouponnot, C., Jayaraman, L. and Massagué, J. (1998) Physical and Functional Interaction of SMADs and p300/CBP. Biological Chemistry, 273, 22865-22868. https://doi.org/10.1074/jbc.273.36.22865
|
[34]
|
Inoue, Y., Itoh, Y., Abe, K., Okamoto, T., Daitoku, H., Fukamizu, A., Onozaki, K. and Hayashi, H. (2007) Smad3 Is Acetylated by p300/CBP to Regulate Its Transactivation Activity. Oncogene, 26, 500-508.
https://doi.org/10.1038/sj.onc.1209826
|
[35]
|
Yuan, H., Reddy, M.A., Sun, G., et al. (2013) Involvement of p300/CBP and Epigenetic Histone Acetylation in TGF-β1-Mediated Gene Transcription in Mesangial Cells. American Journal of Physiology-Renal Physiology, 304, F601-F613. https://doi.org/10.1152/ajprenal.00523.2012
|
[36]
|
Yang, Y., Meng, Q., Wang, C., Li, X., Lu, Y., Xin, X., Zheng, Q. and Lu, D. (2018) MicroRNA 675 Cooperates PKM2 to Aggravate Progression of Human Liver Cancer Stem Cells Induced from Embryonic Stem Cells. Journal of Molecular Medicine (Berlin), 96, 1119-1130. https://doi.org/10.1007/s00109-018-1687-9
|
[37]
|
Merika, M., Williams, A.J., Chen, G., Collins, T. and Thanos, D. (1998) Recruitment of CBP/p300 by the IFN beta Enhanceosome Is Required for Synergistic Activation of Transcription. Molecular Cell, 1, 277-287.
https://doi.org/10.1016/S1097-2765(00)80028-3
|
[38]
|
Ma, C.Q., Huang, S.H., Xu, L., et al. (2020) Transcription Co-Activator P300 Activates Elk1-aPKC-ι Signaling Mediated Epithelial-to-Mesenchymal Transition and Malignancy in Hepatocellular Carcinoma. Oncogenesis, 9, Article No. 32. https://doi.org/10.1038/s41389-020-0212-5
|
[39]
|
Wang, D., Cui, Y., Xu, A., Zhao, L. and Li, P. (2020) MiR-596 Activated by EP300 Controls the Tumorigenesis in Epithelial Ovarian Cancer by Declining BRD4 and KPNA4. Cancer Cell International, 20, Article No. 447.
https://doi.org/10.1186/s12935-020-01497-0
|
[40]
|
Bardhan, K., Paschall, A.V., Yang, D., et al. (2015) IFNγ In-duces DNA Methylation-Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer. Cancer Immunology Research, 3, 795-805.
https://doi.org/10.1158/2326-6066.CIR-14-0164
|
[41]
|
Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y. and He, B. (2019) Zinc-Dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. Current Topics in Medicinal Chemistry, 19, 223-241.
https://doi.org/10.2174/1568026619666190122144949
|
[42]
|
Coiffier, B., Pro, B., Prince, H.M., Foss, F., et al. (2012) Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma after Prior Systemic Therapy. Journal of Clinical Oncology, 30, 631-636. https://doi.org/10.1200/JCO.2011.37.4223
|